News

Restructuring expected to extend cash runway through end of 2020 Acer plans to discuss EDSIVO™ CRL with FDA and will continue to advance additional pipeline products NEWTON, MA – July 5, 2019 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant […]

Enteric-coated formulation offers flexible dosing options, including administration with or without food THIOLA EC expected to be available to patients next month SAN DIEGO, June 28, 2019 (GLOBE NEWSWIRE) — Retrophin, Inc. (NASDAQ: RTRX) today announced that the U.S. Food and Drug Administration (FDA) has approved 100 mg and 300 mg tablets of THIOLA® EC (tiopronin), a new enteric-coated formulation of THIOLA® (tiopronin), […]

Acer Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update Acer continues to progress toward goals of commercializing EDSIVO™ and advancing pipeline NEWTON, MA – March 7, 2019 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with […]

Top-line results from pivotal Phase 3 FORT Study in PKAN expected in 3Q 2019 Two pivotal Phase 3 studies of sparsentan progressing on-track to enable potential first-in-class treatment for both FSGS and IgAN SAN DIEGO, Feb. 26, 2019 (GLOBE NEWSWIRE) — Retrophin, Inc. (NASDAQ: RTRX) today reported its fourth quarter and full year 2018 financial results and provided a […]

Acer acquires worldwide rights to clinical-stage NK3 receptor antagonist NEWTON, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) — Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with critical unmet medical need, today announced that it has entered into an exclusive license […]

Acer continues progress toward goal of commercializing EDSIVO™ NEWTON, Mass., Dec. 26, 2018 (GLOBE NEWSWIRE) — Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has […]

WELLESLEY, MA — November 1st, 2018, Censa Pharmaceuticals Inc., a biopharmaceutical company focused on the development of CNSA-001 for orphan diseases, announced that it has successfully completed a Phase I study and has initiated enrollment into several Phase II studies. The Phase I study showed CNSA-001’s favorable safety profile and promising pharmacokinetic & pharmacodynamic characteristics. […]

PDF Version BOSTON—(BUSINESS WIRE)—Nov. 1, 2018— Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced that new translational data for NiCord®, an investigational cell therapy in Phase 3 clinical development for allogeneic stem cell, or bone marrow, transplant, will be presented at the American Society of Hematology (ASH) 2018 Annual […]

Requests Priority Review NEWTON, MA — October 29, 2018 — Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need, today announced that it has submitted a New Drug Application (NDA) to the U. S. Food and […]

Increasing achievement of FSGS partial remission of proteinuria and stable eGFR observed out to 84 weeks in open-label extension Findings presented at ASN Kidney Week 2018 SAN DIEGO, Oct. 26, 2018 (GLOBE NEWSWIRE) — Retrophin, Inc. (NASDAQ: RTRX) today announced new positive data from the ongoing open-label extension of the Phase 2 DUET Study of […]

Independent Data Monitoring Committee’s (DMC) review of available safety data supports continuing with study as planned; FORT Study now open to pediatric patients aged 6 to 17 Top-line data anticipated in the second half of 2019 SAN DIEGO, June 04, 2018 (GLOBE NEWSWIRE) — Retrophin, Inc. (NASDAQ:RTRX) today announced that the independent Data Monitoring Committee (DMC) for the pivotal […]

Phase 2 Open-Label Trial Investigating Percutaneous Laser Ablation for Treatment of Early-Stage Breast Cancer: MRI, Pathology, and Outcome Correlations

  As At­tenua con­tin­ues to de­velop its lead pro­gram for chronic cough, it will be doing so with $35 mil­lion in the bank and under the lead­er­ship of a new CEO. In con­junc­tion with the Se­ries A fund­ing — led by Omega Funds with par­tic­i­pa­tion from a syn­di­cate that in­cludes Abing­worth, Or­biMed and Red­mile Group […]

SAN DIEGO, April 03, 2018 (GLOBE NEWSWIRE) — Retrophin, Inc. (NASDAQ:RTRX) today announced that the first patient has been enrolled in the DUPLEX Study, a global, pivotal Phase 3 clinical trial evaluating the long-term nephroprotective potential of sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS), a rare kidney disorder that often leads to end-stage renal disease, with no […]

Company appoints new VPs of Clinical Science, Manufacturing, and Finance and hires new Senior Director of Marketing New hires support Acer’s progression from development to potential commercialization of EDSIVOTM   NEWTON, MA – Feb. 5, 2018 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious […]

SAN DIEGO, Jan. 05, 2018 (GLOBE NEWSWIRE) — Retrophin, Inc. (NASDAQ:RTRX) today announced a joint development agreement with Censa Pharmaceuticals, a privately held biotechnology company focused on developing therapies for orphan metabolic diseases, to evaluate CNSA-001 for the treatment of phenylketonuria (PKU). CNSA-001 is an orally bioavailable form of a natural precursor of tetrahydrobiopterin (BH4) […]

Cambridge, MA and THE WOODLANDS, TX – Opexa Therapeutics, Inc. (Nasdaq: OPXA) (“Opexa”) and Acer Therapeutics Inc. (“Acer”), a privately-held pharmaceutical company, today announced that they have entered into a definitive merger agreement under which the stockholders of Acer (including investors in a financing that will close concurrently with the merger) are currently estimated to become […]

Monday, May 01, 2017 Patients become more independent, increasingly mobile, and highly active with 3D printing VALENCIA, Calif.–(BUSINESS WIRE)–May 1, 2017– Millions of people worldwide are impacted by debilitating foot pain, making it difficult to accomplish such daily activities as climbing stairs or taking a walk. Enter 3D printing. Stratasys Direct Manufacturing is now collaborating with Peacocks Medical […]

Friday, March 17, 2017 ASSOCIATE As a key member of our Business Development team, you’ll collaboratively develop strategic plans for our clients and our portfolio companies to enter and expand new business opportunities across several disease areas. Additionally, you’ll drive the business development process with biopharmaceutical companies for products in preclinical and clinical development, as […]

BioInvent International AB (“BioInvent”) (OMXS: BINV), a biotech company focused on the discovery and development of novel immuno-regulatory antibodies to treat cancer, announces that it has entered into a cancer immunotherapy research collaboration and license agreement with Pfizer Inc. (“Pfizer”) (NYSE: PFE) to develop antibodies targeting tumour-associated myeloid cells. Under the terms of the deal, […]

Tuesday, December 13, 2016 CAMBRIDGE, Mass., December 13, 2016 – Acer Therapeutics Inc., a pharmaceutical company developing therapies for serious rare diseases with significant unmet medical need, today announced the signing of an agreement with the Greater Paris University Hospitals AP-HP (via its Department of Clinical Research and Development*) granting the company exclusive rights to […]

Thursday, October 20, 2016 SOUTH SAN FRANCISCO, Calif., Aug. 02, 2016 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on creating and developing novel medicines to address serious medical conditions, today announced that it has entered into a definitive agreement to sell to Attenua, Inc. certain oral Neuronal Nicotinic Receptor (NNR) […]

November 25, 2015 16:56 ET | Source: Vital Images, Inc. MINNEAPOLIS, Nov. 25, 2015 (GLOBE NEWSWIRE) — Vital Images, Inc., (Vital), a leading provider of enterprise imaging solutions, announced a partnership with Stratasys, Ltd. (Nasdaq:SSYS), the 3D printing and additive manufacturing solutions company, to develop an industry first print-on-demand service using Vital’s industry leading Vitrea® […]

Thursday, October 20, 2016 The partnership leverages Stratasys’ 3D printing technology to develop and test new medical devices. (BusinessWire) Stratasys Ltd. has announced that it is partnering with New York-based Jacobs Institute (JI) to create a new Center of Excellence, with the goal of advancing the use of 3D printing for a variety of medical […]

Thursday, October 20, 2016 SOUTH SAN FRANCISCO, Calif., Oct. 18, 2016 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced that it has entered into a definitive agreement to sell one of its neuronal nicotinic receptor (NNR) assets that were under development […]

Monday, July 18, 2016 July 18, 2016 – Cambridge, Massachusetts – Censa Pharmaceutical Inc. completed a Series A round of financing from Arkin Bio Ventures and from senior biopharmaceutical executives. The current financing will allow Censa to aggressively accelerate product development towards regulatory approval in target orphan diseases.   About Censa Pharmaceuticals: Censa Pharmaceuticals Inc. […]

CAMBRIDGE, MA, May 9, 2016 – Acer Therapeutics Inc., a pharmaceutical company developing therapies for serious rare diseases with significant unmet medical need, today announced the company has closed its Series B round with $8.15 million in new investment. Proceeds from the financing will primarily be used to prepare a new drug application (NDA) for […]

Wednesday, December 09, 2015 Groundbreaking Novilase research led by Rose Medical Center’s Dr. Barbara Schwartzberg is presented at San Antonio Breast  Cancer symposium DENVER – A laser treatment called Novilase® Breast Therapy shows promise as a way to successfully treat small breast cancers, according to research that was led by principal investigator Barbara Schwartzberg, M.D. […]

Tuesday, November 17, 2015 IRVINE, Calif., Nov. 16, 2015 /PRNewswire/ — ALPHAEON Corporation today announced the execution of a definitive agreement to acquire substantially all the assets of LENSAR, Inc., a leading global developer and manufacturer of Femtosecond Lasers Systems (FLS), through a wholly owned subsidiary.  The transaction is valued at up to $59 million […]

Thursday, August 20, 2015 BOSTON, Aug. 20, 2015 /PRNewswire/ — Janus Biotherapeutics (Janus) today announced that they have entered into a collaboration with Roche for the development of a small molecule toll-like receptor (TLR) inhibitor with the potential to address several autoimmune diseases. TLRs are an important class of proteins that play a key role in the […]

Thursday, March 19, 2015 Lund, Sweden – 19 March, 2015 – BioInvent International AB (OMXS: BINV) completed a strategic analysis of its ICAM-1 targeted phase II antibody BI-505 with thought leaders to garner support on the development of BI-505. Based on the analysis of BI-505’s data, a clear direction emerged that BI-505 is uniquely positioned to […]

Tuesday, January 20, 2015 Lund, Sweden – 20 January, 2015 – BioInvent International (OMXS: BINV) has today reached an agreement with Cancer Research UK, Cancer Research Technology (CRT), the charity’s development and commercialisation arm, and Leukaemia & Lymphoma Research (LLR) to take its investigational drug, BI-1206, into a collaborative phase I/II trial for patients with chronic […]

Monday, December 01, 2014 Boston, MA — The victim of a vicious crime is the beneficiary of medical innovation and new technology. CBS 2’s Jim Williams reports it gave surgeons a game plan before they entered the operating room. The models helped guide surgeons as they gave a Carmen Tarleton’s life-changing face transplant. “This surgery has […]

Tuesday, October 14, 2014 Orlando, FLA., October 14, 2014 – LENSAR, Inc., a global leader in next generation femtosecond laser technology for refractive cataract surgery, today announced a new commercial alliance with Precision Eye Services, Inc. PES has launched a full service mobile laser cataract solution to surgeons and their patients, providing access to the […]

Thursday, September 11, 2014 Lund, Sweden – 11 September, 2014 – BioInvent International (OMXS: BINV) today announced that it has received another milestone payment from Bayer Pharma AG (Bayer) as the first patient was enrolled in a Phase I clinical trial of a second antibody identified from BioInvent’s n-CoDeR® library. The size of the milestone payment […]

Monday, August 04, 2014 Opthalmology devices maker LensAR secured $8 million in equity funding, according to an SEC filing dated July 31, 2014. The funding round, launched earlier in the month, attracted 2 unnamed investors who closed the round. The new funding joins a $10 million funding round LensAR closed earlier this year. Use of the […]

Wednesday, May 21, 2014 Airport City, Israel., May 21, 2014 – Real Imaging Ltd. today announced that it has received CE Mark designation for its Real Imager 8 device intended for use as adjunct breast cancer screening modality. Real Imaging is the first company to introduce an imaging-based risk assessment system that utilizes 3D functional […]

Thursday, February 13, 2014 Herzeliya, Israel – With preliminary phase IIa data in hand for its postoperative pain treatment PRF-110, Israeli specialty pharmaceutical firm Painreform Ltd. is now seeking takers for the product, which has a 505(b)(2) approval pathway in the U.S. The drug, based on a formulation of the approved local anesthetic ropivacaine, is positioned to […]

Friday, February 07, 2014 DURHAM, N.C. – Argos Therapeutics, Inc. today announced the pricing of its initial public offering of 5,625,000 shares of common stock at a public offering price of $8.00 per share, before underwriting discounts. All of the shares in the offering are being sold by Argos. In addition, the underwriters have an […]

Tuesday, November 12, 2013 The “LENSAR Laser System Lens Softening Study” Opens this Week with the First Case in the United Kingdom; Original Research for the Protocol will be Presented at this Week’s American Academy of  Ophthalmology (AAO) Annual Conference  ORLANDO, FL– LENSAR Inc., developer of the next-generation LENSAR™ Laser System, today announced that is […]

Monday, November 11, 2013 Lund, Sweden – BioInvent International AB (OMXS: BINV) today announces that it has has been granted a US patent for its antibody and concomitant target discovery technology F.I.R.S.T.™. Traditional drug discovery methods involve the identification of drugs candidates that bind to known disease targets. The F.I.R.S.T.™ technology is a novel and […]

Wednesday, October 02, 2013 New Funding Underscores Investor Confidence in the LENSAR™ Laser System’s Role in Refractive Laser-Assisted Cataract Surgery ORLANDO, FL – LENSAR Inc., developer of the next-generation LENSAR™ Laser System for refractive laser-assisted cataract surgery (ReLACS), today announced the closing of $27 million in private equity financing and up to $60 million in […]

Monday, August 26, 2013 Lead Investor Pharmstandard Commits $30 Million and Receives Russian Commercialization Rights  Durham, NC– August 26, 2013 — Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that it has […]

Wednesday, April 03, 2013 ORLANDO, Fla. — LENSAR Inc., developer of the next generation LENSAR Laser System™ for refractive cataract surgery, announced today that the company’s laser system has received 510(k) clearance from the United States Food and Drug Administration (FDA) for the execution of arcuate incisions during cataract surgery. Arcuate incisions are precise incisions […]

Tuesday, January 08, 2013 Accelerates Penetration Into Fast Growing Point-of-Care Market  PEABODY, Mass., Jan. 8, 2013 (GLOBE NEWSWIRE) — Analogic Corporation (Nasdaq:ALOG), enabling the world’s medical imaging and aviation security technology, announced today that it has signed an agreement to acquire privately held Ultrasonix Medical Corporation based in Vancouver, Canada for $83 million in cash. […]

Monday, December 10, 2012 Milestone Expands Range of Indications for Next-Generation Laser Cataract Surgery Platform; System Profiled on Emmy Award-Winning TV Series The Doctors   ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR Inc., developer of the next generation LENSAR Laser SystemTM for refractive cataract surgery, announced today that the company’s laser system has received 510(k) clearance from the United States […]

Tuesday, April 24, 2012 –Arcelis™ Immunotherapy AGS-003 Granted U.S. FDA Fast Track Designation for Treatment of mRCC– Durham, NC– April 24, 2012 —Argos Therapeutics Inc. today announced that it has secured a $25 million Series D financing to support the commencement of its Phase 3 ADAPT study in patients with newly diagnosed, metastatic renal cell carcinoma […]

Monday, March 12, 2012  Company Installs LensAR™ Laser System in the Philippines and Prepares for Second System Installation in Peru    Orlando, FL, March 12, 2012 — LensAR Inc., a developer of the next generation of laser systems for cataract surgery, announced the closing of a $24 million private financing which included investments from Aisling Capital and […]

Saturday, February 04, 2012 Results Support Planned, Randomized Phase 3 ADAPT Study Durham, NC– Feb. 4, 2012 — Argos Therapeutics Inc. today announced that updated results from an open label Phase 2 study of its Arcelis™ immunotherapy, AGS-003, in combination with sunitinib in patients with unfavorable risk, metastatic renal cell carcinoma (mRCC), had demonstrated prolonged survival. […]

Thursday, October 06, 2011 Topcon and LensAR Announce Equity Investment as Part of Strategic Partnership Topcon Europe Medical BV (Rotterdam, Netherlands)(“Topcon”) and LensAR Inc. (Orlando, Florida)(“LensAR”) announce that Topcon has made an equity investment in LensAR in addition to their entering into the long term strategic cooperation announced on September 16th, 2011 which included the […]

Monday, October 03, 2011 Physicians survey confirms value of twice-weekly patch Survey indicates peak sales could exceed $1.1 billion Pivotal patch trials to begin Q4; Phase 3 expected to be completed 2013 MELBOURNE, AUSTRALIA – 10/03/11 – Based on the results of a physician survey commissioned by Phosphagenics Limited (ASX: POH, OTCQX: PPGNY) and conducted in […]

Tuesday, August 30, 2011 GERMANY — Extera Partners announced the expansion of its European Orthopedics/Spine/Trauma organization with the addition of Dr. Eddie Van Eeckhoven as an Associate Vice President. Extera’s European Orthopedics Senior Team members now includes: Andreas Hart (Partner) – Overall project responsibility, sales management, case management Former Managing Director of European Sales at […]

Friday, July 29, 2011 DURHAM, N.C., July 29, 2011 /PRNewswire/ — Argos Therapeutics, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock. All shares of the common stock to be […]

Friday, June 10, 2011 BOSTON– Extera Partners, a global life sciences management firm, announced today that Jefferson Davis and Dr. Michael Thiel have joined Extera as Vice President and Associate Partner, respectively. “Jefferson brings to Extera a significant track-record of business development success, most recently as a senior member of the Genzyme Corporate Development team,” […]

Thursday, May 19, 2011 US-wide clinical trial for first-in-class product to begin mid-2011 AUBURNDALE, Massachusetts-May 19th, 2011- Advantagene, Inc., a Massachusetts based biopharmaceutical company, announced today that it reached an agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment (SPA) for a pivotal Phase 3 clinical trial of ProstAtakTM, its lead agent for patients […]

Wednesday, May 11, 2011 Helsinki, Finland – Nexstim Oy, a medical device company commercializing non-invasive brain diagnostic and therapy technologies, today announced that it has obtained an additional equity financing of EUR 2 million, bringing the latest round to EUR 13.4 million. The latest investment was made by new investor Capricorn Health-tech Fund NV (Belgium). […]

Monday, March 28, 2011 Extera Europe and notified body LNE/G-MED are please to present the free webinar, Accessing the European Medical Device Market: Smart Approaches to CE Marking and Effective Commercialization. This event will take place on April 14, 2011, at 1:00 PM EST. Presented by Dr. Clemens Troche of Extera, and Marc-Henri Winter of notified body LNE/G-MED, this webinar […]

Wednesday, December 22, 2010 Proposed placing of 77,470,412 new Ordinary Shares at 2.5 pence each  XCounter AB (publ) (AIM:XCT) is pleased to announce that it proposes to raise approximately £1.936 million (approximately £1.815 million net of expenses) by way of a Placing of 77,470,412 Placing Shares at a price of 2.5 pence per share. The net […]

Link to Event

Thursday, October 21, 2010 FRAZER, Pa., Oct 21, 2010 /PRNewswire via COMTEX/ — Cephalon, Inc. (Nasdaq: CEPH) announced today that it has exercised its option to acquire BioAssets Development Corporation (BDC), following receipt of interim data from a Phase II placebo-controlled proof-of-concept study evaluating epidural administration of a tumor necrosis factor (TNF) inhibitor for the […]

Tuesday, October 19, 2010 Senior Executive Jean-Pierre Capdevielle Joins Extera Partners to Assist Non-European Medtech Companies with Expansion into Europe BOSTON — Extera Partners, a global life science management firm, announced today that Jean-Pierre Capdevielle has joined the firm as an Associate Partner. Mr. Capdevielle brings thirty years of international sales and marketing experience in the […]

Wednesday, September 08, 2010 Appointments are Latest Milestones in Efforts to Bring LensAR Laser System to Market  Winter Park, FL – LensAR, Inc., the leading developer of next generation laser technology for cataract surgery and presbyopia, today announced the appointments of Nicholas Curtis as the company’s chief commercial officer and Lothar Koob as chief operating […]

Tuesday, July 20, 2010 Addition of Prominent Biotech Dealmaker Solidifies Extera’s Licensing and Transaction Advisory Capabilities BOSTON–(BUSINESS WIRE)–Extera Partners, a global life science strategic and transaction advisory firm, announced today that Steven Bernitz has joined the firm as a General Partner. This addition solidifies Extera’s position as Boston’s most experienced licensing and transaction advisory firm. […]

Thursday, December 10, 2009 HELSINKI–(BUSINESS WIRE)–Nexstim Oy, a medical device company, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Navigated Brian Stimulation System for use in the assessment of the primary motor cortex for pre-procedural planning. Using transcranial magnetic stimulation (TMS) guided by standard MR-image data, Nexstim has developed Navigated […]

Tuesday, November 10, 2009 Industry Veteran Sees Huge Promise in Affordable, High-Quality Digital Radiography Equipment RAANANA, Israel–(BUSINESS WIRE)–EDGE Medical Devices, the developer and manufacturer of Plasma DRTMflat-panel X-ray detector technology and the Universal Retrofit Kit for digital radiography, today announced the appointment of Lothar Koob, General Partner of Extera Partners, to its board of directors. […]

Monday, October 26, 2009 Deal will Provide Cephalon New Path Forward for Development of its Tumor Necrosis Factor Inhibitor  FRAZER, Pa. and WELLESLEY, Mass., Oct. 26 /PRNewswire-FirstCall/ — Cephalon, Inc. (Nasdaq: CEPH) and BioAssets Development Corporation (BDC), a privately held biopharmaceutical company, today announced that the companies have signed an agreement that will provide Cephalon […]

April 16, 2008: Extera Partners today announced that General Partner, Jonathan Reis, MD, MBA, shall moderate a panel focused on the factors determining the roadmap in R&D today. The distinguish panel participants shall include Charles Cooney, PhD, Professor of Chemical and Biochemical Engineering, MIT, Douglas Hart, Professor of Mechanical Engineering, MIT, Founder, Brontes Technology, Christine Brennan, PhD, Director of Strategic […]

Saturday, March 01, 2008 Dr. Robert Parnell who until recently headed business development for Bayer Diagnostics and Bayer Diabetes Care joins Extera Partners to expand its diagnostics advisory capabilities. As a member of Extera’s internal senior executive team, he will work with high-growth IVD and biomarker lifescience companies to accelerate product R&D, business development and […]